Blood
Audio Summaries

How I Treat: MRD testing to personalize allogeneic HCT for adults with AML

Sep 22, 2026

The authors explore how measurable residual disease (MRD) testing can be utilized to personalize allogeneic hematopoietic cell transplantation (allo-HCT) for adults with acute myeloid leukemia (AML). They aim to address the potential of MRD testing in improving patient selection, conditioning regimens, and post-transplant surveillance, while acknowledging the current limitations and uncertainties surrounding its interpretation and application in clinical practice. Through four case studies, the authors illustrate the practical use of MRD testing in managing AML patients undergoing allo-HCT.

Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma

Sep 22, 2026

The authors aimed to investigate how soluble BCMA (sBCMA) levels correlate with tumor burden and prognosis in newly diagnosed multiple myeloma (MM) patients. By analyzing various metrics including bone marrow plasma cell percentage and imaging-defined tumor volumes, they identified four distinct patient phenotypes, revealing that elevated sBCMA levels are a stronger predictor of early treatment failure than tumor volume alone. This multimodal classification framework enhances risk stratification and understanding of MM outcomes based on the interplay between tumor volume and sBCMA levels.

BNP Promotes Platelet Activation and Thrombosis via its Receptor NPRA: A Paradigm Shift from Biomarker to Effector

Sep 22, 2026

The authors investigate whether B-type natriuretic peptide (BNP) directly contributes to cardiovascular disease pathogenesis, particularly in promoting thrombosis, rather than merely serving as a biomarker. Their findings reveal that BNP enhances platelet activation and thrombus formation through its receptor NPRA, suggesting a direct role in increasing thrombotic risk in cardiovascular conditions. This research shifts the understanding of BNP from a simple biomarker to an active effector in thrombotic processes.

Mutant ASXL1 Cooperates with MECOM and BRD4 to Drive Transcriptional Dysregulation in Human Hematopoiesis

Sep 22, 2026

The authors investigate how mutations in the epigenetic regulator ASXL1 contribute to transcriptional dysregulation in human hematopoietic stem cells, which is critical for understanding the poor prognosis associated with ASXL1 mutations in myeloid malignancies. They demonstrate that mutant ASXL1 leads to decreased differentiation and increased clonogenicity, driven by altered transcriptional dynamics and interactions with MECOM and BRD4. This study provides a functional characterization of the ASXL1 mutant interactome, highlighting potential therapeutic targets for ASXL1-mutant myeloid cancers.

JAK3 regulates PIP5K expression, promotes PIP2 generation and Ca2+ driven platelet activation in arterial thrombosis

Sep 21, 2026

The authors investigate how Janus kinase 3 (JAK3) influences phosphatidylinositol 4,5-bisphosphate (PIP2) levels in platelets and its subsequent role in calcium-driven platelet activation during arterial thrombosis. They demonstrate that JAK3 regulates the expression of PIP5K, which is crucial for generating PIP2, thereby facilitating platelet activation and contributing to thrombosis.

Melatonin, circadian metabolism, mitochondrial remodeling, and cell size dynamics in primitive hematopoietic stem cells

Sep 21, 2026

The authors investigate how circadian rhythms and melatonin influence the metabolic state and functionality of primitive hematopoietic stem cells (pHSCs). They demonstrate that nocturnal melatonin levels trigger mitochondrial remodeling and metabolic reprogramming, enhancing pHSCs' regenerative capacity through increased glycolytic activity and structural adaptations. This study highlights the importance of circadian cues in maintaining stem cell fitness and suggests potential clinical implications for hematopoietic stem cell transplantation.

Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia

Sep 18, 2026

The authors aimed to evaluate the impact of adding a tyrosine kinase inhibitor (TKI) to intensive chemotherapy (IC) on the outcomes of patients with de novo BCR::ABL1+ acute myeloid leukemia (AML). Their analysis of 212 patients revealed that the combination of IC and TKI significantly improved complete remission rates and overall survival compared to IC alone, suggesting that this approach should be considered the standard of care and prompting a reevaluation of the classification of this condition as adverse-risk.

IDH3 regulates citrate homeostasis to control metabolic fitness and venetoclax resistance of AML stem cells

Sep 17, 2026

The authors investigate the role of isocitrate dehydrogenase 3 (IDH3) in regulating metabolic fitness and resistance to venetoclax in acute myeloid leukemia (AML) stem cells. They find that IDH3 is crucial for maintaining the tricarboxylic acid (TCA) cycle activity in leukemic stem cells, and its downregulation leads to a metabolic crisis that enhances susceptibility to BCL2 inhibition. The study suggests that targeting the IDH3A-citrate axis could be a potential strategy to overcome treatment resistance in AML patients.

A single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomes

Sep 17, 2026

The authors aimed to investigate the cellular and molecular heterogeneity of large B cell lymphomas (LBCLs) to better understand treatment responses. Through single-cell RNA sequencing and analysis of tumor biopsies, they identified five distinct transcriptional archetypes of malignant B cells, with a specific archetype linked to poor clinical outcomes. This research offers a new framework for patient stratification and potential precision therapies in LBCL treatment.

Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial

Sep 11, 2026

The authors aimed to evaluate the efficacy and safety of recombinant ADAMTS13 (rADAMTS13) compared to plasma-based therapy (PBT) in preventing acute and subacute events in patients with congenital thrombotic thrombocytopenic purpura (TTP). The final analysis of a phase 3 trial demonstrated that rADAMTS13 prophylaxis significantly reduced the occurrence of acute TTP events and treatment-related adverse events, while also enhancing patient satisfaction and maintaining higher ADAMTS13 activity levels compared to PBT. These findings support the clinical benefit of rADAMTS13 as a prophylactic treatment for congenital TTP.